A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells

CG. Langdon (1), N. Wiedemann (2), M. Held (1), J. Platt (1), F. Lévy (2), C. Zann, G. Vuagniaux (2), M. Sorensen (3), S. Wang (4), M. Bosenberg (1), DF. Stern (1)

presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

(1) Yale University, USA

(2) Debiopharm International SA, Switzerland

(3) Ascenta Therapeutics, USA

(4) University of Michigan Cancer Center, USA